{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-025761","form_type":"8-K","ticker":"PBYI","cik":"0001401667","company_name":"PUMA BIOTECHNOLOGY, INC.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.460961+00:00","generated_at":"2026-06-22T08:35:38.795565+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Puma Biotechnology Q3 net loss narrows to $0.4M; raises FY 2022 NERLYNX revenue guidance","bullets":["Q3 product revenue $54.3M, up 25% YoY from $43.4M; net loss $0.4M ($0.01/share) vs $44.7M loss in Q3 2021.","Non-GAAP adjusted net income $2.5M ($0.05/share) vs adjusted loss of $40.4M a year ago.","Raises FY 2022 product revenue guidance to $194-$196M from prior $180-$190M; net income guidance $7-$9M.","In-licensed alisertib (aurora kinase A inhibitor) from Takeda for $7M upfront; plans initial trials in HR+ breast cancer and small cell lung cancer.","Cash and marketable securities $78.0M at Sep 30, 2022; operating cash flow $17.3M in Q3."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-025761","json":"https://secwatch.observer/filing/0001437749-22-025761.json","markdown":"https://secwatch.observer/filing/0001437749-22-025761.md","text":"https://secwatch.observer/filing/0001437749-22-025761.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401667/000143774922025761/0001437749-22-025761-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401667/000143774922025761/pbyi20221101_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:35:38.795565+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9925acc7c91d59c89046ef80dde6b5ed47869543","claim":"PUMA BIOTECHNOLOGY, INC. reported third quarter ended September 30, 2022 results: revenue $54.3 million, net income Net loss of $0.4 million, or $0.01 per share, EPS $0.01 per share. Guidance raised.","evidence_excerpt":"quarter of 2021. Product revenue, net consists entirely of sales revenue from NERLYNX®, Puma’s first commercial product. Product revenue, net in the third quarter of 2022 was $54.3 million, compared to $43.4 million in the third quarter of 2021. Product revenue, net in the first nine months of 2022 was $146.3 million, compared to $138.1 million in the first nine","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401667/000143774922025761/0001437749-22-025761-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$54.3 million"},{"label":"Net income","value":"Net loss of $0.4 million, or $0.01 per share"},{"label":"EPS","value":"$0.01 per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}